Published in Hepatology on October 01, 2005
Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A (2006) 4.54
Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology (2014) 4.15
Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol (2006) 3.75
Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog (2007) 2.98
Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro. J Clin Invest (2010) 2.68
Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences. J Clin Microbiol (2007) 2.55
Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol (2006) 2.55
The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J Virol (2006) 2.48
euHCVdb: the European hepatitis C virus database. Nucleic Acids Res (2006) 2.41
A jumping profile Hidden Markov Model and applications to recombination sites in HIV and HCV genomes. BMC Bioinformatics (2006) 2.25
Genetic history of hepatitis C virus in East Asia. J Virol (2008) 2.20
A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. Nucleic Acids Res (2009) 2.06
The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Med (2009) 2.06
Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol (2008) 1.91
Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus. J Virol (2006) 1.90
Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc Natl Acad Sci U S A (2007) 1.89
Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant. J Virol (2007) 1.87
Hepatitis C virus: virology, diagnosis and management of antiviral therapy. World J Gastroenterol (2007) 1.82
Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc Natl Acad Sci U S A (2008) 1.82
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother (2009) 1.80
Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog (2012) 1.79
MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR. Proc Natl Acad Sci U S A (2011) 1.78
Alcohol and hepatitis C virus--interactions in immune dysfunctions and liver damage. Alcohol Clin Exp Res (2010) 1.77
Plaques Formed by Mutagenized Viral Populations Have Elevated Coinfection Frequencies. MBio (2017) 1.73
Structural and functional characterization of nonstructural protein 2 for its role in hepatitis C virus assembly. J Biol Chem (2008) 1.71
The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus. J Virol (2008) 1.70
The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol (2007) 1.69
Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev (2007) 1.65
Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol (2010) 1.63
Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B. J Biol Chem (2009) 1.61
Current standards in the treatment of chronic hepatitis C. Dtsch Arztebl Int (2012) 1.60
Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. J Virol (2007) 1.59
Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol (2010) 1.55
Consensus proposals for classification of the family Hepeviridae. J Gen Virol (2014) 1.55
Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J Virol (2006) 1.54
Evidence for novel hepaciviruses in rodents. PLoS Pathog (2013) 1.54
A novel diagnostic target in the hepatitis C virus genome. PLoS Med (2009) 1.52
Eighth major clade for hepatitis delta virus. Emerg Infect Dis (2006) 1.51
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother (2010) 1.49
The unique HCV genotype distribution and the discovery of a novel subtype 6u among IDUs co-infected with HIV-1 in Yunnan, China. J Med Virol (2008) 1.49
Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int (2010) 1.48
Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathog (2010) 1.45
The hepatitis C sequence database in Los Alamos. Nucleic Acids Res (2007) 1.45
Identification of determinants involved in initiation of hepatitis C virus RNA synthesis by using intergenotypic replicase chimeras. J Virol (2007) 1.44
Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov (2013) 1.43
Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors. J Infect Dis (2012) 1.43
Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment. J Virol (2013) 1.42
NS4B self-interaction through conserved C-terminal elements is required for the establishment of functional hepatitis C virus replication complexes. J Virol (2011) 1.41
A concerted action of hepatitis C virus p7 and nonstructural protein 2 regulates core localization at the endoplasmic reticulum and virus assembly. PLoS Pathog (2011) 1.41
Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol (2007) 1.40
Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol (2007) 1.38
Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines (2011) 1.37
Identification of a novel determinant for membrane association in hepatitis C virus nonstructural protein 4B. J Virol (2009) 1.37
Genetic variability and the classification of hepatitis E virus. J Virol (2013) 1.36
New trends of HCV infection in China revealed by genetic analysis of viral sequences determined from first-time volunteer blood donors. J Viral Hepat (2011) 1.35
New natural intergenotypic (2/5) recombinant of hepatitis C virus. J Virol (2007) 1.34
Analysis of the 5' noncoding region versus the NS5b region in genotyping hepatitis C virus isolates from blood donors in France. J Clin Microbiol (2006) 1.33
Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One (2009) 1.32
The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog (2012) 1.30
Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology (2010) 1.28
Current progress in development of hepatitis C virus vaccines. Nat Med (2013) 1.28
Nonprimate hepaciviruses in domestic horses, United kingdom. Emerg Infect Dis (2012) 1.28
Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol (2008) 1.27
Hepatitis C virus genotypes in Pakistan: a systemic review. Virol J (2011) 1.27
Production of infectious hepatitis C virus of various genotypes in cell cultures. J Virol (2007) 1.27
NCBI viral genomes resource. Nucleic Acids Res (2014) 1.26
Reproductive clonality of pathogens: a perspective on pathogenic viruses, bacteria, fungi, and parasitic protozoa. Proc Natl Acad Sci U S A (2012) 1.26
Characterization of determinants important for hepatitis C virus p7 function in morphogenesis by using trans-complementation. J Virol (2009) 1.25
Base pairing between hepatitis C virus RNA and microRNA 122 3' of its seed sequence is essential for genome stabilization and production of infectious virus. J Virol (2012) 1.25
Emergence of hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles. J Clin Microbiol (2009) 1.24
Hepatitis C virus infection causes cell cycle arrest at the level of initiation of mitosis. J Virol (2011) 1.24
Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J Gastroenterol (2007) 1.22
Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models. J Infect Dis (2010) 1.21
NMR structure and ion channel activity of the p7 protein from hepatitis C virus. J Biol Chem (2010) 1.21
Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J Gastroenterol (2007) 1.21
Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry. J Virol (2005) 1.21
A meta-analysis of the existing knowledge of immunoreactivity against hepatitis C virus (HCV). PLoS One (2012) 1.20
Lipids and HCV. Semin Immunopathol (2012) 1.19
Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006. World J Gastroenterol (2008) 1.19
Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease. Int J Med Sci (2006) 1.19
Classification of hepatitis C virus and human immunodeficiency virus-1 sequences with the branching index. J Gen Virol (2008) 1.19
Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect. J Virol (2006) 1.16
A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One (2013) 1.16
Evidence of recombination in intrapatient populations of hepatitis C virus. PLoS One (2008) 1.16
An amphipathic alpha-helix at the C terminus of hepatitis C virus nonstructural protein 4B mediates membrane association. J Virol (2009) 1.16
Characterization of hepatitis C virus deletion mutants circulating in chronically infected patients. J Virol (2007) 1.16
Identification of new functional regions in hepatitis C virus envelope glycoprotein E2. J Virol (2010) 1.15
Hepatitis C virus: virology and life cycle. Clin Mol Hepatol (2013) 1.15
Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. Proc Natl Acad Sci U S A (2012) 1.15
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15
Epidemic history of hepatitis C virus infection in two remote communities in Nigeria, West Africa. J Gen Virol (2012) 1.14
Endocytic Rab proteins are required for hepatitis C virus replication complex formation. Virology (2009) 1.14
Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles. J Biol Chem (2009) 1.14
Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol (2011) 1.13
Inactivation and survival of hepatitis C virus on inanimate surfaces. J Infect Dis (2011) 1.13
Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape. PLoS Pathog (2013) 1.09
Genotyping hepatitis C viruses from Southeast Asia by a novel line probe assay that simultaneously detects core and 5' untranslated regions. J Clin Microbiol (2006) 1.09
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Replication of hepatitis C virus. Nat Rev Microbiol (2007) 8.31
The Physcomitrella genome reveals evolutionary insights into the conquest of land by plants. Science (2007) 8.12
The amphioxus genome and the evolution of the chordate karyotype. Nature (2008) 8.03
Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology (2003) 7.35
Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A (2002) 5.81
The medaka draft genome and insights into vertebrate genome evolution. Nature (2007) 5.77
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A (2002) 5.28
Genome sequence of the ultrasmall unicellular red alga Cyanidioschyzon merolae 10D. Nature (2004) 5.08
Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology (2010) 4.58
Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol (2008) 4.55
The genome sequence of silkworm, Bombyx mori. DNA Res (2004) 4.27
Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology (2014) 4.15
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med (2006) 4.14
Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology (2004) 3.98
An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A. J Biol Chem (2001) 3.91
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Structural biology of hepatitis C virus. Hepatology (2004) 3.40
In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A (2003) 3.40
α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology (2013) 3.27
Geno3D: automatic comparative molecular modelling of protein. Bioinformatics (2002) 3.19
Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A (2007) 3.13
Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology (2009) 3.10
The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples. Hepatology (2009) 3.08
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology (2007) 3.08
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
Sporadic acute or fulminant hepatitis E in Hokkaido, Japan, may be food-borne, as suggested by the presence of hepatitis E virus in pig liver as food. J Gen Virol (2003) 2.90
Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. Hepatology (2002) 2.85
Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Liver Transpl (2014) 2.77
Ancient co-speciation of simian foamy viruses and primates. Nature (2005) 2.71
Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. J Virol (2005) 2.63
Helicobacter pylori in North and South America before Columbus. FEBS Lett (2002) 2.57
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis (2006) 2.55
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology (2006) 2.54
Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A (2005) 2.42
euHCVdb: the European hepatitis C virus database. Nucleic Acids Res (2006) 2.41
Topology of the membrane-associated hepatitis C virus protein NS4B. J Virol (2003) 2.37
GB virus C during the natural course of HIV-1 infection: viremia at diagnosis does not predict mortality. AIDS (2004) 2.37
Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology (2002) 2.34
Comparative genomics of Physcomitrella patens gametophytic transcriptome and Arabidopsis thaliana: implication for land plant evolution. Proc Natl Acad Sci U S A (2003) 2.33
Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology (2005) 2.33
Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells. J Biol Chem (2004) 2.32
The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae. J Gen Virol (2010) 2.26
Antiviral strategies in hepatitis C virus infection. J Hepatol (2012) 2.25
A jumping profile Hidden Markov Model and applications to recombination sites in HIV and HCV genomes. BMC Bioinformatics (2006) 2.25
Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing. Hepatology (2013) 2.24
Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology (2002) 2.21
A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol (2009) 2.20
Classifying hepatitis B virus genotypes. Intervirology (2003) 2.20
PDB_REDO: automated re-refinement of X-ray structure models in the PDB. J Appl Crystallogr (2009) 2.19
Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep (2003) 2.16
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology (2006) 2.07
What can be revealed by extending the sensitivity of HBsAg detection to below the present limit? J Hepatol (2008) 2.05
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A (2012) 2.05
Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology (2007) 2.03
Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol (2012) 2.03
A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A (2002) 2.02
Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology (2003) 2.02
Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis (2005) 2.02
Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma. Gastroenterology (2012) 2.00
Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol (2009) 2.00
Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J Virol (2006) 1.99
EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer (2006) 1.97
Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology (2006) 1.96
The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc Natl Acad Sci U S A (2003) 1.93
Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun (2004) 1.93
Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol (2004) 1.92
Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. J Virol (2002) 1.89
Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol (2006) 1.88
Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. Gastroenterology (2007) 1.88
Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol (2012) 1.86
MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis C virus NS3/4A protease. J Virol (2008) 1.86
A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology (2011) 1.85
Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology (2005) 1.85
HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology (2004) 1.83
Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc Natl Acad Sci U S A (2008) 1.83
Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology (2007) 1.83
Hepatitis C virus: virology, diagnosis and management of antiviral therapy. World J Gastroenterol (2007) 1.82
Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc Natl Acad Sci U S A (2008) 1.82
Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol (2002) 1.82
Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol (2002) 1.81
Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol (2010) 1.80
Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog (2012) 1.79
MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR. Proc Natl Acad Sci U S A (2011) 1.78
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology (2003) 1.78
Membrane association of hepatitis C virus nonstructural proteins and identification of the membrane alteration that harbors the viral replication complex. Antiviral Res (2003) 1.76
Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int (2011) 1.75